ERic Acute StrokE Recanalization

• Verfasst von: Siemonsen, Susanne [VerfasserIn]
• Verfasst von: Bendszus, Martin [VerfasserIn]
• Titel: ERic Acute StrokE Recanalization
• Titelzusatz: a study using predictive analytics to assess a new device for mechanical thrombectomy
• Verf.angabe: Susanne Siemonsen, Nils D Forkert, Martina Bernhardt, Götz Thomalla, Martin Bendszus and Jens Fiehler
• E-Jahr: 2017
• Jahr: March 22, 2017
• Umfang: 8 S.
• Fussnoten: Article first published online: March 22, 2017 ; Gesehen am 27.08.2018
• Titel Quelle: Enthalten in: International journal of stroke
• Ort Quelle: London : Sage, 2006
• Jahr Quelle: 2017
• Band/Heft Quelle: 12(2017), 6, Seite 659-666
• ISSN Quelle: 1747-4949
• DOI: doi:10.1177/1747493017700661
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1580397662

Abstract

Aim and hypothesisUsing a new study design, we investigate whether next-generation mechanical thrombectomy devices improve clinical outcomes in ischemic stroke patients. We hypothesize that this new methodology is superior to intravenous tissue plasminogen activator therapy alone.Methods and designERic Acute StrokE Recanalization is an investigator-initiated prospective single-arm, multicenter, controlled, open label study to compare the safety and effectiveness of a new recanalization device and distal access catheter in acute ischemic stroke patients with symptoms attributable to acute ischemic stroke and vessel occlusion of the internal cerebral artery or middle cerebral artery.Study outcomeThe primary effectiveness endpoint is the volume of saved tissue. Volume of saved tissue is defined as difference of the actual infarct volume and the brain volume that is predicted to develop infarction by using an optimized high-level machine learning model that is trained on data from a historical cohort treated with IV tissue plasminogen activator.Sample size estimatesBased on own preliminary data, 45 patients fulfilling all inclusion criteria need to complete the study to show an efficacy >38% with a power of 80% and a one-sided alpha error risk of 0.05 (based on a one sample t-test).DiscussionERic Acute StrokE Recanalization is the first prospective study in interventional stroke therapy to use predictive analytics as primary and secondary endpoint. Such trial design cannot replace randomized controlled trials with clinical endpoints. However, ERic Acute StrokE Recanalization could serve as an exemplary trial design for evaluating nonpivotal neurovascular interventions.